Historical source coverage

2018, page 2

260 selected records with a cited source date in 2018, shown 200 per page, newest first. This archive is selective and does not imply continuous monitoring or complete historical coverage.

Explore 2018 by record type

3 types

June 2018

9 records on this page

Clinical trials · Glatiramer acetate

ClinicalTrials.gov record NCT00078338

PeptideScanner retained ClinicalTrials.gov record NCT00078338 at 2026-11-16T17:42:50.457Z. Its registry update date was 2018-06-27, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

Source: ClinicalTrials.gov ↗

→

Literature metadata · GHK-Cu

PubMed record PMID 28370978

PeptideScanner retained PubMed bibliographic metadata for PMID 28370978 at 2026-07-30T21:12:28.721Z. PubMed recorded a metadata revision date of 2018-06-25 and an Entrez history date of 2017-04-04. PeptideScanner associated this retained record with the identity slug ghk-cu. These dates describe PubMed metadata history, not the article's original publication date.

Source: PubMed ↗

→

Clinical trials · Glatiramer acetate

ClinicalTrials.gov record NCT01569451

PeptideScanner retained ClinicalTrials.gov record NCT01569451 at 2026-11-16T17:42:50.457Z. Its registry update date was 2018-06-08, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

Source: ClinicalTrials.gov ↗

→

May 2018

5 records on this page

Literature metadata · Cibinetide

ARA 290 for treatment of small fiber neuropathy in sarcoidosis.

PubMed lists PMID 24555851 in Expert opinion on investigational drugs as Journal Article, Review, with publication-date metadata of 2014-02-21 (day precision). PeptideScanner associated the retained record with the identity slug cibinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Glatiramer acetate

Pharmacologic Treatment of Rett Syndrome With Glatiramer Acetate.

PubMed lists PMID 27363291 in Pediatric neurology as Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2016-05-27 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

April 2018

6 records on this page

Regulatory · Lixisenatide

Federal Register notice 2018-07256

The Federal Register published notice 2018-07256, attributed to FDA and its parent HHS department, on 2018-04-10. Its official title is “Notice of Approval of Products Under Voucher: Rare Pediatric Disease Priority Review Vouchers,” and PeptideScanner's exact reviewed identity mapping connects the document to Lixisenatide.

Source: Federal Register via GovInfo ↗

→

Literature metadata · KPV

PubMed record PMID 28343991

PeptideScanner retained PubMed bibliographic metadata for PMID 28343991 at 2026-07-30T21:12:28.720Z. PubMed recorded a metadata revision date of 2018-04-05 and an Entrez history date of 2017-03-28. PeptideScanner associated this retained record with the identity slug kpv. These dates describe PubMed metadata history, not the article's original publication date.

Source: PubMed ↗

→

March 2018

13 records on this page

Regulatory · Oxytocin

Federal Register rule 2018-06358

The Federal Register published rule 2018-06358, attributed to FDA and its parent HHS department, on 2018-03-30. Its official title is “New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Applications; Changes of Sponsorship; Change of a Sponsor's Name and Address,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin.

Source: Federal Register via GovInfo ↗

→

Literature metadata · Semax

Influence of ACTG4-7-PGP (Semax) on Morphofunctional State of Hepatocytes in Chronic Emotional and Painful Stress.

PubMed lists PMID 28577097 in Bulletin of experimental biology and medicine as Journal Article, with publication-date metadata of 2017-06-03 (day precision). PeptideScanner associated the retained record with the identity slug semax. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Pramlintide

Zn(II) - pramlintide: Stability, binding sites and unexpected aggregation.

PubMed lists PMID 28672144 in Journal of inorganic biochemistry as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2017-06-23 (day precision). PeptideScanner associated the retained record with the identity slug pramlintide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Semax

Influence of the N-terminus acetylation of Semax, a synthetic analog of ACTH(4-10), on copper(II) and zinc(II) coordination and biological properties.

PubMed lists PMID 27586814 in Journal of inorganic biochemistry as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2016-08-27 (day precision). PeptideScanner associated the retained record with the identity slug semax. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

February 2018

18 records on this page

Clinical trials · Leuprolide

ClinicalTrials.gov record NCT01120236

PeptideScanner retained ClinicalTrials.gov record NCT01120236 at 2026-07-30T21:12:47.407Z. Its registry update date was 2018-02-26, and PeptideScanner's reviewed identity mapping was leuprolide.

Source: ClinicalTrials.gov ↗

→

Literature metadata · Dalbavancin

Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections.

PubMed lists PMID 29258361 in Expert opinion on drug metabolism & toxicology as Comparative Study, Journal Article, Review, with publication-date metadata of 2017-12-25 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Clinical trials · Linaclotide

ClinicalTrials.gov record NCT00730171

PeptideScanner retained ClinicalTrials.gov record NCT00730171 at 2026-07-30T21:12:47.419Z. Its registry update date was 2018-02-19, and PeptideScanner's reviewed identity mapping was linaclotide.

Source: ClinicalTrials.gov ↗

→

Literature metadata · Lanreotide

The use of new somatostatin analogues, lanreotide and octastatin, in neuroendocrine gastro-intestinal tumours.

PubMed lists PMID 8813476 in Digestion as Clinical Trial, Journal Article, Multicenter Study, with publication-date metadata of 1996 (year precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Clinical trials · Vasopressin

ClinicalTrials.gov record NCT01393704

PeptideScanner retained ClinicalTrials.gov record NCT01393704 at 2026-11-15T22:08:31.832Z. Its registry update date was 2018-02-15, and PeptideScanner's reviewed identity mapping was vasopressin.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Octreotide

ClinicalTrials.gov record NCT02217800

PeptideScanner retained ClinicalTrials.gov record NCT02217800 at 2026-07-30T21:12:47.415Z. Its registry update date was 2018-02-15, and PeptideScanner's reviewed identity mapping was octreotide.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Nesiritide

ClinicalTrials.gov record NCT01977859

PeptideScanner retained ClinicalTrials.gov record NCT01977859 at 2026-11-16T01:39:41.882Z. Its registry update date was 2018-02-14, and PeptideScanner's reviewed identity mapping was nesiritide.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Eptifibatide

ClinicalTrials.gov record NCT01103440

PeptideScanner retained ClinicalTrials.gov record NCT01103440 at 2026-11-15T21:59:29.646Z. Its registry update date was 2018-02-14, and PeptideScanner's reviewed identity mapping was eptifibatide.

Source: ClinicalTrials.gov ↗

→

Literature metadata · Emideltide

PubMed record PMID 3758119

PeptideScanner retained PubMed bibliographic metadata for PMID 3758119 at 2026-07-30T21:13:34.042Z. PubMed recorded a metadata revision date of 2018-02-14 and an Entrez history date of 1986-01-01. PeptideScanner associated this retained record with the identity slug emideltide. These dates describe PubMed metadata history, not the article's original publication date.

Source: PubMed ↗

→

Regulatory · Glatiramer acetate

Drugs@FDA application ANDA206921

The official Drugs@FDA dataset lists original submission 1 for ANDA 206921 with status AP dated 2018-02-12, and names glatiramer acetate among the application record's active ingredients.

Source: Drugs@FDA via openFDA ↗

→

Regulatory · Dalbavancin

Federal Register notice 2018-02768

The Federal Register published notice 2018-02768, attributed to FDA and its parent HHS department, on 2018-02-12. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; DALVANCE,” and PeptideScanner's exact reviewed identity mapping connects the document to Dalbavancin.

Source: Federal Register via GovInfo ↗

→

Regulatory · Leuprolide

Federal Register notice 2018-02667

The Federal Register published notice 2018-02667, attributed to FDA and its parent HHS department, on 2018-02-09. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.

Source: Federal Register via GovInfo ↗

→

Literature metadata · TB-500

PubMed record PMID 28887173

PeptideScanner retained PubMed bibliographic metadata for PMID 28887173 at 2026-07-30T21:13:36.164Z. PubMed recorded a metadata revision date of 2018-02-08 and an Entrez history date of 2017-09-10. PeptideScanner associated this retained record with the identity slug tb-500. These dates describe PubMed metadata history, not the article's original publication date.

Source: PubMed ↗

→

Clinical trials · Glatiramer acetate

ClinicalTrials.gov record NCT00856635

PeptideScanner retained ClinicalTrials.gov record NCT00856635 at 2026-11-16T17:42:50.457Z. Its registry update date was 2018-02-06, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Pasireotide

ClinicalTrials.gov record NCT02021942

PeptideScanner retained ClinicalTrials.gov record NCT02021942 at 2026-11-15T22:05:38.400Z. Its registry update date was 2018-02-05, and PeptideScanner's reviewed identity mapping was pasireotide.

Source: ClinicalTrials.gov ↗

→

January 2018

9 records on this page

Regulatory · Lutetium Lu 177 dotatate

Drugs@FDA application NDA208700

The official Drugs@FDA dataset lists original submission 1 for NDA 208700 with status AP dated 2018-01-26, and names lutetium lu-177 dotatate among the application record's active ingredients.

Source: Drugs@FDA via openFDA ↗

→

Clinical trials · Liraglutide

ClinicalTrials.gov record NCT02140983

PeptideScanner retained ClinicalTrials.gov record NCT02140983 at 2026-07-30T21:12:47.414Z. Its registry update date was 2018-01-25, and PeptideScanner's reviewed identity mapping was liraglutide.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Liraglutide

ClinicalTrials.gov record NCT01272219

PeptideScanner retained ClinicalTrials.gov record NCT01272219 at 2026-07-30T21:12:47.414Z. Its registry update date was 2018-01-19, and PeptideScanner's reviewed identity mapping was liraglutide.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Etelcalcetide

ClinicalTrials.gov record NCT01134562

PeptideScanner retained ClinicalTrials.gov record NCT01134562 at 2026-11-15T22:07:29.454Z. Its registry update date was 2018-01-02, and PeptideScanner's reviewed identity mapping was etelcalcetide.

Source: ClinicalTrials.gov ↗

→